Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02633-w ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Takuto Hara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Quinolines, Antibodies, Monoclonal, Humanized, Phenylurea Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Combined treatment with lenvatinib and pembrolizumab is currently regarded as one of the standard first-line therapies for advanced renal cell carcinoma (aRCC) patients. The objective of this study was to assess the efficacy and safety of this combined regimen in treatment-naïve Japanese aRCC patients. METHODS: This study included a total of 50 consecutive aRCC patients receiving combined lenvatinib plus pembrolizumab in routine clinical practice in Japan, and comprehensively analyzed clinical outcomes of this treatment. RESULTS: Of these 50, 7 (14.0%), 23 (46.0%) and 20 (40.0%) were classified into favorable, intermediate and poor risk groups, respectively, according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) system. Responses to this combined therapy in the 50 patients were as follows: complete response, 7 (14.0%); partial response, 26 (52.0%); stable disease, 15 (30%) and progressive disease, 2 (4%); thus, the objective response rate (ORR) was 66%. ORRs in favorable, intermediate and poor risk groups were 57.1, 69.6 and 65.0%, respectively. During the observation period, disease progression and death occurred in 14 (28.0%) and 6 (12.0%) patients, respectively, and neither the median PFS nor OS was reached. Adverse events and those corresponding to grade ≥ 3 were observed in all (100%) and 33 (66.0%) patients, respectively. CONCLUSIONS: To our knowledge, this is the first study focusing on real-world outcomes of lenvatinib and pembrolizumab for treatment-naïve aRCC patients, showing that the efficacy and safety of this combined regimen are similar to those noted in randomized clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
- Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.
- Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. hmiyake@med.kobe-u.ac.jp.
Zitieren
APA
Hara, T., Suzuki, K., Okamura, Y., Chiba, K., Sato, R., Matsushita, Y., Tamura, K., Ishikawa, G., Otsuka, A., & Miyake, H. (2024). Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02633-w
Vancouver
Hara T, Suzuki K, Okamura Y, Chiba K, Sato R, Matsushita Y, et al. Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02633-w
BibTeX
@article{Hara2024,
author = {Hara, Takuto and Suzuki, Kotaro and Okamura, Yasuyoshi and Chiba, Koji and Sato, Ryo and Matsushita, Yuto and Tamura, Keita and Ishikawa, Gaku and Otsuka, Atsushi and Miyake, Hideaki},
title = {Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02633-w}
}
EUVIMED